Asteria Health recalled 1,015 testosterone pellets on January 26, 2026 due to potential metal particulate contamination. The recall affects products distributed nationwide in the United States. Consumers must stop using the pellets immediately and contact their healthcare provider for guidance.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Testosterone pellets are used in hormone replacement therapy for men with low testosterone levels. Consumers typically purchase these products to manage symptoms associated with low testosterone, such as fatigue and decreased libido.
The potential presence of metal particulate matter in the testosterone pellets poses serious health risks if ingested. Metal contaminants can lead to adverse health effects, including toxicity and organ damage.
This recall is not part of a broader industry pattern.
The recall affects consumers who rely on testosterone therapy for their health needs. Stopping usage is necessary to prevent potential health risks.
The lot number and expiration date are typically located on the product packaging or label.
Expect a refund processing timeline of 4-6 weeks after submission of your request.
Keep records of your purchase, including receipts and any correspondence with the manufacturer or healthcare provider.
The recalled product is Testosterone, 303 mg, 1 Sterile Pellet, manufactured by F.H. INVESTMENTS, Inc. The affected lot number is 251000124 with an expiration date of June 2, 2026.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Asteria Health recalled 133 estradiol pellets on January 26, 2026, after detecting potential metal particulate matter. The recall, classified as Class II, affects pellets with lot number 253000126 and an expiration date of June 9, 2026. Consumers must stop using the product immediately and contact their healthcare provider for guidance.
Asteria Health recalled 60,868 testosterone pellets on January 26, 2026, due to contamination risks. The recall affects specific lots of the product that may contain metal particulate matter. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Asteria Health recalled 89,074 testosterone pellets on January 26, 2026. The recall stems from potential metal particulate contamination. Consumers must stop using the product and contact their healthcare provider immediately.
Asteria Health recalled 22,478 Estradiol 12.5 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers and healthcare providers must stop using the product immediately. The FDA classified this recall as Class II, indicating a high hazard level.
Asteria Health recalled 24,099 Estradiol, 10 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately. The recall affects pellets distributed nationwide in the USA.
Asteria Health recalled 50,990 Estradiol pellets on January 26, 2026, due to potential metal particulate matter contamination. The recall affects products distributed nationwide in the USA. Consumers should stop using the pellets immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,699 sterile estradiol pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately and contact their healthcare provider for advice. The recall affects pellets distributed nationwide in the USA.
Asteria Health recalled 1,464 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. The recall affects products distributed nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.